Aytu Bioscience (AYTU) could be COVID-19 test kit winner
Aytu Bioscience (AYTU) currently trades at $1.54 and has fallen by 1.91% today. AYTU went down #0.03 from the previous closing price of $1.57. The high forecast for Aytu Bioscience is $5.00 and the low is $2.00. The company’s market cap is $89.60 million with a 52 week high of $2.99 and a 52 week low of $0.34. AYTU has changed in price by -0.44 per share in the last 12 months. The company it has sold/allocated 100K COVID-19 antibody blood tests in the U.S. and is expecting delivery of another 500K. It has boosted the size of its third order to 1M.
Aytu Bioscience has a weak EPS of -1.16. This means the company lost $-1.16 per share after paying dividends, this can indicate that the stock is a risky investment. EPS is calculated as a company’s profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company’s profitability. It is common for a company to report EPS that is adjusted for extraordinary items and potential share dilution. Based on this information, investorsQ rates this stock 5 out of 10. We give it this rating based on current information written in this article.
About Aytu Bioscience:
Aytu BioScience, Inc. operates as a specialty healthcare company. The Company concentrates on acquiring, developing, and commercializing products focused primarily on sexual disfunction disorders, urological cancer, urinary tract infections, and male infertility. Aytu Bioscience serves patients and customers worldwide.